The Optimal Management of Polycythaemia Vera

Spivak, Jerry L.

doi:10.1046/j.1365-2141.2002.03287.x

Cited by 46 publications

(37 citation statements)

References 194 publications

(221 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…On the other hand, persistence of endogenous erythroid colony formation and bone marrow hyperplasia despite normalization of blood counts have been described in IFN-treated PV patients. 7,16 In this work, because we performed no marrow examination and single-cell colony assays, we could not precisely evaluate the size of the JAK2 mutated clone under treatment. Thus, IFN-␣ may reduce the rate of clonal proliferation without expanding the population of normal cells.…”

Section: Resultsmentioning

confidence: 99%

High molecular response rate of polycythemia vera patients treated with pegylated interferon -2a

Kiladjian

Cassinat

Turlure

et al. 2006

Blood

233

163

View full text Add to dashboard Cite

V617F JAK2 mutation is a reliable molecular marker of polycythemia vera (PV), potentially useful to monitor the effect of treatments in this disease. In a phase 2 study of pegylated (peg) IFN-␣-2a in PV, we performed prospective sequential quantitative evaluation of the percentage of mutated JAK2 allele (%V617F) by realtime polymerase chain reaction (PCR). The %V617F decreased in 24 (89%) of 27 treated patients, from a mean of 49% to a mean of 27% (mean decrease of 44%; P < .001), and no evidence for a plateau was observed. In one patient, mutant JAK2 was no longer detectable after 12 months. In 3 patients homozygous for the mutation, reappearance of 50% of wildtype allele was observed during treatment. The results seem to confirm the hypothesis that IFN-␣ preferentially targets the malignant clone in PV and show that %V617F assessment using a quantitative method may provide the first tool to monitor minimal residual disease in PV. This trial was registered at www. clinicaltrials.gov as #NCT00241241. (Blood.

show abstract

Section: Resultsmentioning

confidence: 99%

High molecular response rate of polycythemia vera patients treated with pegylated interferon -2a

Kiladjian

Cassinat

Turlure

et al. 2006

Blood

233

163

View full text Add to dashboard Cite

show abstract

“…Its use may be accompanied by side effects that are not easily tolerated by many elderly patients. 9 …”

Section: Introductionmentioning

confidence: 99%

Diagnosis and treatment of polycythemia vera: Brazilian experience from a single institution

2008

View full text Add to dashboard Cite

CONTEXT AND OBJECTIVE: Polycythemia vera (PV) is a chronic myeloproliferative disorder characterized by predominant proliferation of erythroid precursors. Few data are available concerning Brazilian patients with this condition. The aim of this study was to describe clinical and demographic characteristics of PV patients at diagnosis and analyze their long-term outcomes. DESIGN AND SETTING: Retrospective study at the Division of Hematology, Faculdade de Medicina da Universidade de São Paulo (FMUSP), São Paulo. METHODS: All consecutive patients with PV diagnosed according to World Health Organization criteria were eligible for this study. Clinical and demographic characteristics, thrombotic events, transformation to acute leukemia, myelofibrosis and survival were evaluated. RESULTS: Sixty-six patients were evaluated. Thirty-six (54.5%) were females, with a median age at diagnosis of 61 years. At diagnosis, the median hemoglobin concentration was 18.8 mg/dl and the median platelet count was 593,000/mm³. Fifty-eight patients (88.0%) were treated with hydroxyurea with or without phlebotomy. During a median follow-up of 77 months, 22 patients (33.3%) had new thrombotic events, mainly of arterial type. The overall incidence of leukemia and myelofibrosis was 0.42% per patient-year and 1.06% per patient-year, respectively. Median overall survival was not reached and the seven-year survival rate was 77.8%. CONCLUSION: The PV patients described here had long survival and arterial thrombotic events were the most important and common complication among this population.

show abstract

“…As the viscosity increases, cerebral blood flow decreases correspondingly [5,6] . Platelet marginalize leading to increased contact to blood vessel walls , along with local effect of a high hematocrit on vessel walls [5,6] .…”

mentioning

confidence: 99%

“…Platelet marginalize leading to increased contact to blood vessel walls , along with local effect of a high hematocrit on vessel walls [5,6] . All of this factors contribute to the enhanced thrombogenicity seen in Polycythemia Vera [5,6,7,8] . There are case reports which propose a microembolic mechanism from heart.…”

mentioning

confidence: 99%

“…Hydoxyurea (HU) is the agent of choice in such cases. In the PVSG trial, HU therapy reduced the risk of thrombosis compared with phlebotomy alone and should be the drug of choice for patients older than 40 years (5,11) . The ECLAP (The Italian study, European Collaboration on Low-dose Aspirin in PV) found aspirin efficacious for preventing thrombosis and also controlling erythromelalgia, which result from spontaneous platelet aggregation.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Ischemic Stroke as the Initial Presenting Manifestation of Polycythemia Rubra Vera- A Case Report

Yadav¹

2017

jmscr

View full text Add to dashboard Cite

The Optimal Management of Polycythaemia Vera

Cited by 46 publications

References 194 publications

High molecular response rate of polycythemia vera patients treated with pegylated interferon -2a

High molecular response rate of polycythemia vera patients treated with pegylated interferon -2a

Diagnosis and treatment of polycythemia vera: Brazilian experience from a single institution

Ischemic Stroke as the Initial Presenting Manifestation of Polycythemia Rubra Vera- A Case Report

Contact Info

Product

Resources

About